Markets:

Overview

News

Currencies

International

Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

13.10 +0.03 (+0.23%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

2 Supercharged Growth Stocks to Buy Right Now ↗

May 14, 2023

These two biopharma stocks might be poised for a major breakout.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 12, 2023

Via Benzinga

US Stock Futures Signal Strong Finish To Wobbly Week — But Analyst Still Sees Recession Risk On Horizon ↗

May 12, 2023

Via Benzinga

Amylyx Blows Past Sales Expectations, Reports Unexpected Profit — Shares Rocket ↗

May 11, 2023

The company was expected to post another loss, but instead came in with a gain of 2 cents per share.

Via Investor's Business Daily

Amylyx Pharma Earnings Preview ↗

May 10, 2023

Via Benzinga

3 Biotechs That Might Get Bought Out in 2023 ↗

April 26, 2023

Biotech is expected to be a hotbed of mergers and acquisitions this year.

Via The Motley Fool

Analyst Ratings for Amylyx Pharma ↗

March 31, 2023

Via Benzinga

Expert Ratings for Amylyx Pharma ↗

March 31, 2023

Via Benzinga

Looking Into Amylyx Pharmaceuticals's Return On Capital Employed ↗

March 15, 2023

Via Benzinga

Analyst Expectations for Amylyx Pharma's Future ↗

March 14, 2023

Via Benzinga

Amylyx Pharmaceuticals - An Emerging Leader In ALS ↗

April 12, 2023

Amylyx has sold off from its earnings report on March 13th. What has been driving this move and what does it mean for the long term prospects of Amylyx?

Via Talk Markets

7 Biotech Stocks to Buy for 100% Returns ↗

April 09, 2023

If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023 ↗

March 31, 2023

Via Benzinga

Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review ↗

March 17, 2023

A market rally is underway, but bank stocks kept tumbling.

Via Investor's Business Daily

Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today ↗

March 14, 2023

The biopharma's new ALS drug is exceeding projections on the sales front.

Via The Motley Fool

Amylyx, A Top 5% Biotech Stock, Just Scored A Huge Win In ALS Treatment ↗

March 14, 2023

Analysts saw just $4.7 million in sales of Relyvrio. Amylyx blew that out of the water.

Via Investor's Business Daily

Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 14, 2023

Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a...

Via Benzinga

First Republic Bank, PacWest Bancorp, Western Alliance Bancorporation And Other Big Stocks Moving Higher On Tuesday ↗

March 14, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining more than 200 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Amylyx: An "Ice Bucket" Buy ↗

November 06, 2022

The drug was green-lighted by the Food & Drug Administration last month, after clinical trials partially funded by Ice Bucket Challenge grants showed that Relyvrio takers had a median survival period...

Via Talk Markets

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 14, 2023

Via Benzinga

Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

March 14, 2023

Raymond James raised the price target for Jabil Inc. (NYSE: JBL) from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 on...

Via Benzinga

Why PacWest Bancorp Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket ↗

March 14, 2023

Gainers PacWest Bancorp (NASDAQ: PACW) rose 29.9% to $12.66 in pre-market trading after multiple insider buys by Officers, Directors reported late Monday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

March 14, 2023

We're starting off the day with an overview of the biggest pre-market stock movers investors need to keep an eye on for Tuesday!

Via InvestorPlace

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 13, 2023

Via Benzinga

Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data ↗

February 14, 2023

Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.

Via Benzinga

100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles ↗

December 30, 2022

Energy and medical plays top the 100 Best Stocks of 2022. It makes sense, given world events that shifted the first-quarter playing field.

Via Investor's Business Daily

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗

November 16, 2022

Neurodegenerative disorders could mean big bucks for some biotechs.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Cytokinetics CEO: Why It's OK Not Being An Overnight Success ↗

October 25, 2022

The company hopes to come out next year with at least one heart-failure drug.

Via Investor's Business Daily

Vyant Bio Inc. (NASDAQ: VYNT): Leading a New Biotech Move to Combat Diseases Affecting the Nervous System ↗

October 04, 2022

Biotechnology companies such as Biogen Inc. (NASDAQ: BIIB), Alector Inc.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

Headline News about Amylyx Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today